But what's the best way to find the right combination of stocks? Because funding things like your retirement, your kids' college tuition, or your short- and long-term savings goals will definitely require significant returns. What is the Zacks Rank? Agreement is the extent to which all brokerage analysts are revising their earnings estimates in the same direction. The greater the percentage of analysts revising their estimates higher, the better chance the stock will outperform. Upside is the difference bet ...

Inventory Turnover, Receivables Turnover, Asset Utilization, and Operating Margin greater than the industry average Veracyte (VCYT) is a global diagnostics company that provides clinicians with valuable insights to diagnose and treat cancer. VCYT has an average four-quarter earnings surprise of 59.7%. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, ...

A month has gone by since the last earnings report for Veracyte (VCYT) . Shares have added about 8.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Veracyte due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Veracyte's Q1 Loss Lower Than Expected,'24 Sales View Up ...

Veracyte (VCYT) closed the last trading session at $21.45, gaining 9.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $29.83 indicates a 39.1% upside potential. The mean estimate comprises six short-term price targets with a standard deviation of $5.71. While the lowest estimate of $21 indicates a 2.1% decline from the current price level, the most optimistic analyst expects the ...

Over the past four weeks, VCYT has gained 9.6%. The company is currently ranked a Zacks Rank #1 (Strong Buy), another strong indication the stock could move even higher. Once investors consider VCYT's positive earnings estimate revisions, the bullish case only solidifies. No estimate has gone lower in the past two months for the current fiscal year, compared to 2 higher, and the consensus estimate has increased as well. Given this move in earnings estimate revisions and the positive technical factor, invest ...

Irrespective of market conditions, companies with favorable efficiency levels are more likely to be investors' choices. The reason is that a company with a favorable efficiency level is expected to offer impressive returns as it is believed to be positively correlated to its price performance. Efficiency ratio is an indication of a company's financial health. It analyzes how efficiently a company uses its assets and liabilities internally. However, at times it becomes difficult to measure the efficiency lev ...

Veracyte, Inc. (VCYT) , a leading name in cancer diagnostics, is set to showcase compelling data from three studies demonstrating the capabilities of its Afirma GRID (Genomic Resource for Intelligent Discovery) tool at ENDO 2024 from Jun 1-4. These findings promise to enhance the personalization of thyroid cancer treatment, marking a significant step forward in the molecular testing landscape. By enhancing the depth and accuracy of molecular testing, Veracyte's Afirma GRID tool is poised to play a crucial r ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I ...

Financial Data and Key Metrics Changes - The company reported first-quarter revenue of $96.8 million, a 17% increase compared to the prior year period, driven by a 25% growth in the testing business [17][31] - Total testing volume reached approximately 33,500 tests, reflecting a 16% increase year-over-year [31] - Non-GAAP gross margin was 68%, down approximately 70 basis points year-over-year, while testing ASP was approximately $2,900 [34][32] Business Line Data and Key Metrics Changes - Decipher Prostate tests delivered 16,500 units, achieving a new quarterly volume record, with growth from both new and existing providers [5][17] - Afirma reported approximately 14,000 test results, with a 14% revenue growth compared to the prior year [21] - Biopharmaceutical and other revenue was $3 million, down 51% year-over-year due to overall spending constraints across the industry [33] Market Data and Key Metrics Changes - The American Cancer Society estimates approximately 300,000 new cases of prostate cancer in 2024, indicating a growing market for Decipher [11] - The company aims for 80% penetration in both Prostate and Fibroid Cancer Molecular Tests, indicating a significant market opportunity [9] Company Strategy and Development Direction - The company is focused on global expansion through a robust IVD strategy and solving new cancer challenges via its diagnostics platform [25][58] - The acquisition of C2i genomics is expected to enhance the company's offerings in Minimal Residual Disease (MRD) testing [12][29] - The company plans to launch its first MRD test for muscle-invasive bladder cancer in the first half of 2026 [58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Decipher, citing strong market penetration and the impact of updated NCCN guidelines [39][49] - The company raised its total revenue guidance for 2024 to $402 million to $410 million, reflecting an improved outlook for its testing business [36] - Management acknowledged challenges in enrollment for the NIGHTINGALE trial but remains optimistic about the market potential for the nasal swab test [27][42] Other Important Information - The company downsized commercial support for the InvisioTest but will continue to offer it to patients facing interstitial lung disease [26] - The updated NCCN guidelines for Decipher Prostate received a level 1b evidence rating, the highest for gene expression tests for prostate cancer [19] Q&A Session Summary Question: Growth rate for Decipher and market penetration - Management indicated that Decipher's growth is driven by market penetration, share gains, and overall market growth, with a 30% year-over-year volume increase and a 36% revenue growth [68] Question: Enrollment slowdown in NIGHTINGALE trial - Management noted that enrollment challenges are typical in large multi-site trials and are not indicative of market interest [42][43] Question: Biopharma-related activities and revenue potential - Management acknowledged a pipeline of new customers and projects in biopharma, indicating potential for future growth despite current constraints [77] Question: Demand for Afirma GRID and clinician interest - Management reported significant interest from academic settings and rural communities, indicating a positive trend for Afirma [81] Question: Medicare reimbursement impact on Afirma - Management clarified that while TERT testing provides some benefit, it is not expected to significantly uplift ASP due to limited patient selection [83] Question: Development strategy for MRD testing - Management expressed confidence in launching the MRD test for muscle-invasive bladder cancer by early 2026, emphasizing control over the necessary assessments [97]

| --- | --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Q1 2024 Business and Financial Presentation | | | | | | | | | | | | May 7, 2024 | | | | | Forward-looking statements and non-GAAP information Total Revenue by Quarter1 $72.4 $81.7 $82.0 $90.4 $90.3 $3.9 $4.0 $4.0 $3.7 $3.5 $6.1 $4.6 $4.1 $4.1 $3.0 $82.4 $90.3 $90.1 $98.2 $96.8 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Testi ...